Hematology

Children exposed to residential pesticides are at a higher risk of developing pediatric hematopoietic cancers, a new study has found.

Regardless of insurance status, patients with multiple myeloma can expect financial hardships-even those making over $100,000 a year, according to a study published online in Lancet Haematology.

A new study has found that nonbiological factors including marital status, county-level income, and insurance status may also affect the chances of survival among young patients with acute myelogenous leukemia (AML).

David Carbone, MD, PhD, a survivor of lymphoma and director, James Thoracic Center, The Ohio State University Comprehensive Cancer - The James, discusses pain management in the context of being a patient and a physician.

Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses the challenges with treating patients with multiple myeloma.

Kim Noonan, MS, RN, ANP, AOCN, chief nurse practitioner, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the challenges of treating patients with multiple myeloma.

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

A new study has found that patients with lower vitamin D levels prior to treatment for follicular lymphoma are more likely to die or relapse from the disease earlier than patients with adequate vitamin D levels in their blood.

The FDA has approved deferasirox (Jadenu) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease, and thalassemia.

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some new treatments on the horizon for T-cell lymphoma.

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses some of the side effects that come with new agents approved for the treatment of non-Hodgkin Lymphoma.

The FDA's approval of panobinostat (Farydak) for multiple myeloma, the first histone deacetylase (HDAC) inhibitor to be approved in this space, provides a new option and new hope for patients with this disease, Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation, said.

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years.

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don't adhere to their medication.

The year 2014 was distinguished by dramatic progress in cancer care, perhaps nowhere more so than in the treatment of blood cancers.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the risk factors for developing myelodysplastic syndromes(MDS).

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

Jenna Forsythe, MSN, RN, OCN, a nurse in the leukemia and lymphoma outpatient center at John Theurer Cancer Center, discusses some of the challenges patients with leukemia and lymphoma face.

A new diagnosis of acute leukemia can pose an immediate threat to life given the substantial morbidity and mortality associated with the disease.

Linda Casey, BSN, OCN, a nurse at the John Theurer Cancer Center, discusses working with and treating patients who are diagnosed with blood cancer.

Louise Eaton, RN, BSN, OCN, inpatient Stem Cell Transplant Unit, John Theurer Cancer Center, provides advice for the relationship between caregivers and patients undergoing stem cell transplantation, as well as responsibilities for caregivers.

The recent extended approval of ibrutinib for the treatment of Waldenström's macroglobulinemia (WM), the disease's first FDA-approved therapy, has provided new hope for patients with the orphan disease.

Jenna Forsythe, MSN, RN, OCN, a nurse in the leukemia and lymphoma outpatient center at John Theurer Cancer Center, discusses updates in leukemia treatment and the effect it has had in practice.

Linda Casey, BSN, OCN, a nurse at the John Theurer Cancer Center, discusses distress screening for patients undergoing cancer treatment.

Louise Eaton, RN, BSN, OCN, inpatient Stem Cell Transplant Unit, John Theurer Cancer Center, gives advice on how nurses should manage patients undergoing stem cell transplantation.

The FDA's calendar for making decisions on new oncology drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Michelle Gervino, RN, BSN, OCN, John Theurer Cancer Center, discusses side effects that patients with hematologic malignancies may experience during treatment

Part 2 of an overview and explanation of current cutaneous lymphoma treatments.

Results of a large retrospective study of more than 20,000 women treated for early-stage breast cancer are shedding light on how much treatment may be too much for these early-stage cancers.

Considering participation in a clinical trial is often a very difficult decision for patients, especially those dealing with a rare disease.